Akebia Therapeutics/$AKBA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Ticker

$AKBA
Primary listing

Industry

Biotechnology

Employees

181

ISIN

US00972D1054

AKBA Metrics

BasicAdvanced
$953M
-
-$0.21
0.88
-

What the Analysts think about AKBA

Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.

Bulls say / Bears say

Akebia Therapeutics reported strong Q1 2025 financial results, with total net product revenues of $55.8 million, including $12.0 million from the successful U.S. launch of Vafseo® (vadadustat) for anemia in dialysis patients. (globenewswire.com)
The company achieved a net income of $6.1 million in Q1 2025, a significant turnaround from a net loss of $18.0 million in Q1 2024, indicating improved financial health. (globenewswire.com)
Akebia strengthened its financial position by completing a $50 million public offering, ending Q1 2025 with $113.4 million in cash, providing a solid foundation for future growth. (globenewswire.com)
Despite the successful launch of Vafseo®, Akebia's total revenues for the full year 2024 were $160.18 million, a 17.70% decrease compared to 2023, indicating potential challenges in sustaining revenue growth. (stockanalysis.com)
The company's operating expenses remain high, with selling, general, and administrative expenses accounting for 44.9% of revenue and research and development expenses at 17.0% in Q1 2025, which could impact profitability. (marketbeat.com)
Akebia's total debt stands at $46.5 million, with a long-term debt to total capital ratio of 65.4%, indicating significant leverage that may pose financial risks. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

AKBA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AKBA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AKBA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs